Global company The Binding Site has chosen Birmingham-based Cure Leukaemia as its charity partner for 2013/14.
The Specialist Protein Company, that employs over 400 people at its offices in Edgbaston, will be supporting Cure Leukaemia with a host of exciting fundraising activities throughout the year.
The Binding Site is Cure Leukaemia’s first charity partner to introduce payroll donations a method many employees have already signed up to. The company joins Deloitte, Pinsent Masons, OGL Computer, Aston Villa Football Club and Warwickshire County Cricket Club on Cure Leukaemia’s high profile roster of supporters.
The International Company is committed to developing innovative immunodiagnostic procedures with extensive expertise in antibody specificity technology, which allows clinicians and laboratory staff the tools to significantly improve diagnosis and management of patients.
For over twenty-five years The Binding Site have specialised in producing highly sensitive and highly specific antibodies used for the detection of certain cancers and other serious disorders.
Along with the Birmingham headquarters the Binding Site also has offices in Germany, The USA, Belgium, Spain, Italy, The Czech Republic and France and the global company continues to grow year on year.
Charles de Rohan, CEO of The Binding Site in Birmingham, said:
“We are very proud to be supporting a local charity that is very close to our hearts. Similar to Cure Leukaemia, our business is all about helping save the lives of patients through providing innovative, accessible blood tests. We have already seen the excellent, ground-breaking work that Cure Leukaemia help facilitate at the Clinical Centre For Haematology and we’re very excited that it will be the focus of our fundraising activities this year.”
James McLaughlin, CEO of Cure Leukaemia, said:
“We’re delighted to have been recognised by a company which is achieving global excellence. The company's Charity Committee have some fantastic fundraising activities lined up and we’re very much looking forward to working with them to help us reach our £1 million fundraising target for the year ahead.”
Cure Leukaemia's £1m Centre Appeal 2017